Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.51 |
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 7/20 | 0.51 |
| ▸ | LMNA | P02545 | 6/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | IDH1 | O75874 | 4/20 | 0.47 |
| ▸ | ACLY | P53396 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2055411 | 0.92 | KMT2A (0.54) | KMT2AMAPTMEN1LMNANPSR1 | |
| SCHEMBL2055417 | 0.80 | RECQL (0.60) | KMT2AMAPTMEN1LMNAHTT | |
| SCHEMBL1320934 | 0.79 | MEN1 (0.52) | KMT2AMAPTMEN1LMNAHTT | |
| SCHEMBL17103025 | 0.78 | MEN1 (0.63) | KMT2AMAPTMEN1LMNANPSR1 | |
| SCHEMBL17102991 | 0.76 | MAPT (0.65) | KMT2AMAPTMEN1LMNANPSR1 | |
| SCHEMBL7808166 | 0.76 | MEN1 (0.64) | KMT2AMAPTMEN1LMNANPSR1 | |
| SCHEMBL17103006 | 0.74 | MEN1 (0.64) | KMT2AMAPTMEN1LMNANPSR1 | |
| SCHEMBL15145840 | 0.74 | LMNA (0.70) | KMT2AMAPTMEN1LMNANPSR1 | |
| SCHEMBL20846986 | 0.73 | MEN1 (0.63) | KMT2AMAPTMEN1LMNANPSR1 | |
| SCHEMBL1110317 | 0.73 | ACLY (0.63) | KMT2AMEN1LMNAACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163911-B2 | Arylsulfonylaminomethylphosphonic acid derivatives, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-24 | — | — | US | disclosed |
| US-20100261677-A1 | ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261677-A1 | ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | ARSA, SULT2A1, PMM2 | KMT2A 494/4885MAPT 4830/4885MEN1 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.